Wall Street analysts expect ICU Medical, Incorporated (NASDAQ:ICUI) to post sales of $333.90 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for ICU Medical’s earnings, with the lowest sales estimate coming in at $330.50 million and the highest estimate coming in at $337.30 million. ICU Medical reported sales of $343.24 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 2.7%. The firm is scheduled to issue its next earnings report on Thursday, November 8th.
According to Zacks, analysts expect that ICU Medical will report full-year sales of $1.37 billion for the current year, with estimates ranging from $1.37 billion to $1.38 billion. For the next year, analysts forecast that the business will post sales of $1.40 billion, with estimates ranging from $1.40 billion to $1.41 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover ICU Medical.
ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, August 9th. The medical instruments supplier reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $1.82 by $0.84. ICU Medical had a return on equity of 12.78% and a net margin of 5.93%. The company had revenue of $360.46 million for the quarter, compared to the consensus estimate of $337.60 million. During the same quarter last year, the business posted $0.76 EPS. ICU Medical’s quarterly revenue was up 8.7% compared to the same quarter last year.
In related news, VP Thomas D. Mccall sold 11,133 shares of the firm’s stock in a transaction that occurred on Friday, August 24th. The stock was sold at an average price of $302.56, for a total value of $3,368,400.48. Following the sale, the vice president now owns 3,018 shares of the company’s stock, valued at approximately $913,126.08. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Pfizer Inc sold 700,000 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $284.35, for a total value of $199,045,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 711,920 shares of company stock worth $202,651,956. Company insiders own 12.50% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in ICUI. Oakbrook Investments LLC increased its position in ICU Medical by 35.8% in the 3rd quarter. Oakbrook Investments LLC now owns 2,275 shares of the medical instruments supplier’s stock valued at $643,000 after acquiring an additional 600 shares during the period. Louisiana State Employees Retirement System increased its position in ICU Medical by 9.8% in the 3rd quarter. Louisiana State Employees Retirement System now owns 4,500 shares of the medical instruments supplier’s stock valued at $1,272,000 after acquiring an additional 400 shares during the period. First Hawaiian Bank acquired a new stake in ICU Medical in the 3rd quarter valued at approximately $226,000. Bank of Montreal Can increased its position in ICU Medical by 35.3% in the 3rd quarter. Bank of Montreal Can now owns 48,288 shares of the medical instruments supplier’s stock valued at $13,654,000 after acquiring an additional 12,588 shares during the period. Finally, Personal Capital Advisors Corp increased its position in ICU Medical by 4.4% in the 3rd quarter. Personal Capital Advisors Corp now owns 17,399 shares of the medical instruments supplier’s stock valued at $4,920,000 after acquiring an additional 735 shares during the period. 74.29% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:ICUI opened at $271.08 on Friday. ICU Medical has a 52 week low of $180.45 and a 52 week high of $321.70. The company has a market cap of $5.79 billion, a price-to-earnings ratio of 50.00 and a beta of 0.41.
ICU Medical Company Profile
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
See Also: Outstanding Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.